Skip to main content

Nemaura Medical Launches Beta Version of Its Metabolic Health Program

Written by Customer Service on . Posted in Public Companies.

MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare

LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or “the Company”), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application.

Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, will discuss MiBoKo in more detail during his corporate presentation scheduled for today, September 29, 2021 at 11:10 a.m. ET during the Benzinga Healthcare Small Cap Conference. Investors can access this presentation by registering for the conference at https://www.benzinga.com/events/small-cap/healthcare/

MiBoKo, which has been in development for the past 18 months, addresses a significant mass market opportunity that the Company believes could benefit roughly a third to half of the population by using a noninvasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns, or even those looking to maintain better health through more careful glucose control, could benefit from such a metabolic health program.

MiBoKo’s next-level health tracking program uses a small and comfortable sensor and a mobile app to provide users with personalized information by tracking their metabolism. A user can find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health.

“A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels, and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease and dementia,” explains Dr. Chowdhury. “With MiBoKo, we are able to extend our proprietary noninvasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health. At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant healthcare needs for large patient populations. We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.”

Along with the capability to follow metabolic health progress on an app, a MiBoKo user receives weekly and monthly reports that show and explain their body’s unique metabolic health score and a breakdown of how each of their habits are impacting their overall health and wellbeing. Suggestions for small, manageable changes to daily routines, such as eating more or less of a certain kind of food or exercising at a different time of day to coincide with peak energy levels, provide MiBoKo users with personalized, usable data.

Anyone interested in participating as a MiBoKo user can now register for the beta program at www.MiBoKo.com. There is no cost during the beta period, with approved MiBoKo beta testers receiving the sensors and AI program free of charge. The initial beta launch is intended for North America, the U.K. and Europe. Further details of the program can be found at www.MiBoKo.com.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.